This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2016 May 5;374(18):1795-6.

doi: 10.1056/NEJMc1515131.

Reevaluating PSA Testing Rates in the PLCO Trial

Jonathan E Shoag¹, Sameer Mittal¹, Jim C Hu²

Affiliations

PMID: 27144870
DOI: 10.1056/NEJMc1515131

Reevaluating PSA Testing Rates in the PLCO Trial

Jonathan E Shoag et al. N Engl J Med. 2016.

. 2016 May 5;374(18):1795-6.

doi: 10.1056/NEJMc1515131.

Authors

Jonathan E Shoag¹, Sameer Mittal¹, Jim C Hu²

Affiliations

¹ New York Presbyterian Hospital, New York, NY jes9171@nyp.org.
² Weill Cornell Medical College, New York, NY.

PMID: 27144870
DOI: 10.1056/NEJMc1515131

No abstract available

PubMed Disclaimer

Comment in

Re: Re-evaluating PSA Testing Rates in the PLCO Trial.
Roobol MJ. Roobol MJ. Eur Urol. 2016 Oct;70(4):700-701. doi: 10.1016/j.eururo.2016.07.036. Epub 2016 Aug 2. Eur Urol. 2016. PMID: 27495847 No abstract available.
Re: Reevaluating PSA Testing Rates in the PLCO Trial.
Taneja SS. Taneja SS. J Urol. 2016 Oct;196(4):1123-5. doi: 10.1016/j.juro.2016.07.065. Epub 2016 Jul 18. J Urol. 2016. PMID: 27628793 No abstract available.
More on Reevaluating PSA Testing Rates in the PLCO Trial.
Shoag JE, Mittal S, Hu JC. Shoag JE, et al. N Engl J Med. 2016 Oct 13;375(15):1500-1501. doi: 10.1056/NEJMc1607379. N Engl J Med. 2016. PMID: 27732806 No abstract available.
More on Reevaluating PSA Testing Rates in the PLCO Trial.
Pinsky P, Prorok P. Pinsky P, et al. N Engl J Med. 2016 Oct 13;375(15):1500-1501. doi: 10.1056/NEJMc1607379. N Engl J Med. 2016. PMID: 27732807 No abstract available.
Re: Reevaluating PSA Testing Rates in the PLCO Trial.
Albers P. Albers P. Eur Urol. 2017 Feb;71(2):300. doi: 10.1016/j.eururo.2016.10.039. Epub 2016 Nov 4. Eur Urol. 2017. PMID: 27823819 No abstract available.
PSA-Screening – Ergebnis der PLCO-Studie fehlerhaft.
[No authors listed] [No authors listed] Aktuelle Urol. 2016 Dec;47(6):444. doi: 10.1055/s-0036-1597164. Epub 2016 Dec 29. Aktuelle Urol. 2016. PMID: 28033615 German. No abstract available.

Similar articles

Screening for prostate cancer: the current evidence and guidelines controversy.
Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R. Gomella LG, et al. Can J Urol. 2011 Oct;18(5):5875-83. Can J Urol. 2011. PMID: 22018148 Review.
Re: Reevaluating PSA Testing Rates in the PLCO Trial.
Albers P. Albers P. Eur Urol. 2017 Feb;71(2):300. doi: 10.1016/j.eururo.2016.10.039. Epub 2016 Nov 4. Eur Urol. 2017. PMID: 27823819 No abstract available.
More on Reevaluating PSA Testing Rates in the PLCO Trial.
Pinsky P, Prorok P. Pinsky P, et al. N Engl J Med. 2016 Oct 13;375(15):1500-1501. doi: 10.1056/NEJMc1607379. N Engl J Med. 2016. PMID: 27732807 No abstract available.
More on Reevaluating PSA Testing Rates in the PLCO Trial.
Shoag JE, Mittal S, Hu JC. Shoag JE, et al. N Engl J Med. 2016 Oct 13;375(15):1500-1501. doi: 10.1056/NEJMc1607379. N Engl J Med. 2016. PMID: 27732806 No abstract available.
The Melbourne Consensus Statement on the early detection of prostate cancer.
Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ. Murphy DG, et al. BJU Int. 2014 Feb;113(2):186-8. doi: 10.1111/bju.12556. BJU Int. 2014. PMID: 24206066 Review.

See all similar articles

Cited by

Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health: Cohort study protocol.
Bernal-Soriano MC, Parker LA, López-Garrigos M, Hernández-Aguado I, Caballero-Romeu JP, Gómez-Pérez L, Alfayate-Guerra R, Pastor-Valero M, García N, Lumbreras B. Bernal-Soriano MC, et al. Medicine (Baltimore). 2019 Oct;98(40):e17451. doi: 10.1097/MD.0000000000017451. Medicine (Baltimore). 2019. PMID: 31577771 Free PMC article.
Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines.
Shah N, Ioffe V, Huebner T, Hristova I. Shah N, et al. Rev Urol. 2018;20(2):77-83. doi: 10.3909/riu0793. Rev Urol. 2018. PMID: 30288144 Free PMC article.
Prosteria - National Trends and Outcomes of More Frequent Than Guideline Recommended Prostate Specific Antigen Screening.
Peterson DJ, Bhambhvani HP, Baird DRW, Li S, Eisenberg ML, Brooks JD. Peterson DJ, et al. Urology. 2023 Apr;174:92-98. doi: 10.1016/j.urology.2023.01.011. Epub 2023 Jan 26. Urology. 2023. PMID: 36708931 Free PMC article.
Male Oncology Research and Education program for men at high risk for prostate cancer.
Lorentz J, Liu SK, Vesprini D. Lorentz J, et al. Curr Oncol. 2018 Apr;25(2):170-175. doi: 10.3747/co.25.3818. Epub 2018 Apr 30. Curr Oncol. 2018. PMID: 29719433 Free PMC article.
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.
Fleshner K, Carlsson SV, Roobol MJ. Fleshner K, et al. Nat Rev Urol. 2017 Jan;14(1):26-37. doi: 10.1038/nrurol.2016.251. Epub 2016 Dec 20. Nat Rev Urol. 2017. PMID: 27995937 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal